Last reviewed · How we verify

NCT05404893

Fecal Calprotectin Levels in Patients With Fibromyalgia

Completed Last updated 18 January 2023
What this trial tests

trial testing Fecal calprotectin measurement in Fibromyalgia in 100 participants. Completed in 30 September 2022.

Timeline
1 April 2022
Primary endpoint
7 June 2022
30 September 2022

Quick facts

Lead sponsorEge University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date1 April 2022
Primary completion7 June 2022
Estimated completion30 September 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ege University

Who can join

18 and older, any sex, with Fibromyalgia or Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was designed to evaluate fecal calprotectin levels in patients with fibromyalgia syndrome. Fecal calprotectin levels from fibromyalgia patients with and without gastrointestinal symptoms as well as healthy controls will be measured and compared.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

Other Ege University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05404893.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing